SR101099 - Moligand™ , Antagonist of UT receptor, CAS No.S613689, Antagonist of UT receptor

CAS: S613689 Cat. No.: S613689
DISPONIBLE À COMMANDE
QUALITÉ & PURETÉ Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools.
Storage
Room temperature
★
Taille
USA
Allemagne (EU)*
Prix
Qté
5mg
S613689-5mg
Sur commande · 8–12 semaines
799,90$US
25mg
S613689-25mg
Sur commande · 8–12 semaines
1 714,90$US
Enter a quantity for the sizes you want to add.

Spécifications

Spécifications et pureté
Moligand™
Conditions de stockage de stockage
Room temperature
Grade
Moligand™
Type d'action
ANTAGONIST
Mécanisme d'action
Antagonist of UT receptor
Noms et identifiants
SMILES
CN(CCCOc1cc(ccc1Cl)c1nc(ccc1c1ccccc1C)C(=O)NC1(CCCCC1)C(=O)O)C
IUPAC Name
1-[[6-[4-chloro-3-[3-(dimethylamino)propoxy]phenyl]-5-(2-methylphenyl)pyridine-2-carbonyl]amino]cyclohexane-1-carboxylic acid
InChIKey
XCIGPFMHSRYJDG-UHFFFAOYSA-N
InChI
1S/C31H36ClN3O4/c1-21-10-5-6-11-23(21)24-13-15-26(29(36)34-31(30(37)38)16-7-4-8-17-31)33-28(24)22-12-14-25(32)27(20-22)39-19-9-18-35(2)3/h5-6,10-15,20H,4,7-9,16-19H2,1-3H3,(H,34,36)(H,37,38)
Isomères SMILES
CC1=CC=CC=C1C2=C(N=C(C=C2)C(=O)NC3(CCCCC3)C(=O)O)C4=CC(=C(C=C4)Cl)OCCCN(C)C.Cl
Reaxy-Rn
19748311
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=19748311&ln=

Données avancées

Taxonomic Classification

Taxonomy Tree

KingdomOrganic compounds
SuperclassOrganic acids and derivatives
ClasseCarboxylic acids and derivatives
SubclassAmino acids, peptides, and analogues
Intermediate Tree Nodes Amino acids and derivatives - Alpha amino acids and derivatives - N-acyl-alpha amino acids and derivatives
Direct ParentN-acyl-alpha amino acids
Alternative Parents Phenylpyridines  Pyridinecarboxylic acids and derivatives  Phenoxy compounds  Phenol ethers  2-heteroaryl carboxamides  Toluenes  Alkyl aryl ethers  Chlorobenzenes  Aryl chlorides  Heteroaromatic compounds  Trialkylamines  Secondary carboxylic acid amides  Amino acids  Monocarboxylic acids and derivatives  Azacyclic compounds  Carboxylic acids  Hydrocarbon derivatives  Organic oxides  Carbonyl compounds  Organochlorides  
Molecular FrameworkAromatic heteromonocyclic compounds
Substituents N-acyl-alpha-amino acid - 2-phenylpyridine - 3-phenylpyridine - Pyridine carboxylic acid or derivatives - 2-heteroaryl carboxamide - Phenoxy compound - Phenol ether - Alkyl aryl ether - Chlorobenzene - Halobenzene - Toluene - Aryl chloride - Pyridine - Benzenoid - Aryl halide - Monocyclic benzene moiety - Heteroaromatic compound - Tertiary aliphatic amine - Tertiary amine - Secondary carboxylic acid amide - Amino acid - Carboxamide group - Azacycle - Organoheterocyclic compound - Carboxylic acid - Monocarboxylic acid or derivatives - Ether - Hydrocarbon derivative - Amine - Organic nitrogen compound - Organohalogen compound - Carbonyl group - Organochloride - Organonitrogen compound - Organooxygen compound - Organic oxygen compound - Organic oxide - Aromatic heteromonocyclic compound
DescriptionThis compound belongs to the class of organic compounds known as n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom.
External Descriptors Not available
Structure 3D
Modèle de structure chimique interactif





Cibles associées (humaines)
UTS2R Tchem Urotensin-2 receptor (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
Certificats (CoA, COO, BSE/TSE et tableau d'analyse)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Calculateurs de solution
Avis

Avis des clients

Application Protocols

Item-specific (from Product Data)

  • No tested application protocols or recommended dilutions are provided for SR101099.

General guidance for screening workflows

  • Plate preparation: Thaw DMSO stocks at ambient temperature; centrifuge briefly to collect condensate. Spot into assay plates using calibrated liquid handlers. Seal promptly to minimize evaporation.
  • Controls: Include vehicle (DMSO) controls, positive reference inhibitors/agonists where applicable, and detergent controls for aggregation-prone targets.
  • Concentration–response: Use at least 8–12 points (1:3 or 1:2 serial dilutions) to estimate potency metrics robustly.
  • Data quality: Monitor Z′, signal-to-background, and edge effects. Repeat hits in independent preparations and with orthogonal readouts.

Note

  • Refer to your institutional SOPs for specific assay modalities (enzymatic, binding, cell viability, reporter gene, etc.).
Biological Roles

Item-specific (from Product Data)

  • No biological function/target annotations are provided for SR101099.

General positioning for screening compounds

  • SR101099 is supplied as a research-use small molecule within a compound library. It does not have an assigned biological role from the supplier. Any biological activity must be established empirically in the user’s assays.

Best practices

  • Profile potential assay interferences (fluorescence, redox cycling, metal chelation, aggregation) before attributing mechanistic roles.
  • If activity is observed, confirm with orthogonal binding/functional assays and generate preliminary structure–activity relationships (SAR) with close analogs.
  • Record pH-dependent effects and media components (serum, albumin, detergents) that can alter apparent potency via binding or solubilization.

Important notice

  • For research use only. Not intended for diagnostic, therapeutic, or in vivo use.
Buffer Applications

Not typically applicable

  • SR101099 is a discrete small molecule rather than a buffering agent. No buffer capacity or buffer formulation role is provided or expected.

Practical note (general)

  • When preparing assay-ready solutions, dissolve in DMSO first (if needed), then dilute into the appropriate biological buffer (e.g., HEPES, PBS) keeping final DMSO low (≤0.5–1% v/v) to maintain assay fidelity. Adjust buffer pH to favor solubility based on ionization data once available.
Green Alternatives

Context

  • Specific synthetic or solvent use for SR101099 is not defined. The guidance below addresses greener handling of small-molecule stocks and routine lab operations.

Greener choices (general)

  • Stock solvents: Prefer water and biocompatible buffers where feasible; if organic is required, ethanol and isopropanol are generally greener than DMF/NMP. DMSO, while not on many preferred lists, offers low volatility and broad solvency, reducing repeated preparations and waste.
  • Workup/purification: If the compound is used in synthesis/purification, consider ethyl acetate/hexane or heptane systems rather than chlorinated solvents; replace dichloromethane with cyclopentyl methyl ether (CPME) or 2-MeTHF when reaction compatibility allows.
  • Energy use: Room-temperature operations and ambient-pressure processes reduce energy demand; SR101099 is stored at room temperature per Product Data, aligning with low-energy storage.

Tradeoffs

  • DMSO vs ethanol: DMSO offers superior solvency and stability but is less preferred in some green metrics; ethanol is greener but can have limited solvency and higher volatility.
  • CPME/2-MeTHF vs DCM: Greener ethers are less dense and have better safety profiles but can form peroxides and may be less effective for some extractions; apply routine peroxide testing and scavenging.

Implementation

  • Document solvent rationale in ELN. Track solvent volumes to target reductions. Validate greener substitutions with small-scale pilot runs.
Pharmaceutical Uses

Not applicable for excipient/clinical use

  • SR101099 is provided strictly for research use only (per Product Data). No pharmacopeial status, excipient role, or clinical manufacturing use is indicated.

General context

  • In early discovery, screening compounds may serve as tool molecules or preliminary hits in target validation. Any transition toward development requires rigorous re-synthesis, full analytical characterization, impurity profiling, and safety assessments.

Documentation reminder

  • Do not use in GMP processes or human/animal administration. Maintain research-only segregation and labeling in inventory systems.
Physical Properties

Item-specific (from Product Data)

  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Physical state, color, odor: Not specified for this item; refer to CoA/Spec Sheet.
  • Melting/Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
  • Density, refractive index: Not specified for this item; refer to CoA/Spec Sheet.
  • Solubility: Not specified for this item; refer to CoA/Spec Sheet.
  • LogP/LogD, pKa: Not specified for this item; refer to CoA/Spec Sheet.

General guidance (literature/typical for small-molecule screening solids)

  • Many heteroaromatic drug-like molecules are crystalline solids with melting points in the 80–250 C range (literature, broad range).
  • DMSO is the default solvent for 10–50 mM screening stocks; aqueous solubility can vary widely with pH and salt formation.
  • For unknown ionization behavior, assess aqueous solubility across pH 2, 7.4, and 9 buffers; consider cosolvents (≤2% DMSO) for biochemical assays.

Practical tips

  • Determine actual solubility gravimetrically or by nephelometry before plate production.
  • If hygroscopic or polymorphic behavior is suspected, record Karl Fischer (water) and DSC/TGA profiles (general QC practice; not item-specific).
Quality and Grades

Item-specific (from Product Data)

  • Grade/Purity: Moligand™ (purity value not specified; refer to CoA/Spec Sheet).

What Moligand™ typically implies (general explanation)

  • Moligand™ denotes a discovery/screening-oriented small-molecule suitable for biochemical/cellular assay exploration, SAR initiation, and library inclusion. Such materials are generally provided with structure identity, basic purity, and storage guidance appropriate for HTS/fragment/ligand screening workflows. Exact acceptance criteria (e.g., HPLC area %, NMR identity, residual solvents) vary by item and must be confirmed on the CoA.

Quality considerations for screening compounds (general)

  • Identity: Verify by LC–MS and 1H NMR against the structural file prior to first use.
  • Purity: For assay reliability, ≥95% HPLC area% is common in screening collections; if lower, confirm that impurities do not interfere with readouts (general practice; not item-specific).
  • Counter-ion/salt form: Confirm free base/acid vs. salt; this affects molarity calculations and solubility.
  • Solid state: Record batch-specific form (polymorph/solvate) if relevant to dissolution.
  • Trace specifications (water, peroxides, metals, UV cutoffs): Not specified for this item; refer to CoA/Spec Sheet.

Documentation

  • Retain batch CoA, SDS, and analytical spectra in your ELN/LIMS, indexed to SKU S613689 and any internal barcodes.
Reaction and Applications

Item-specific (from Product Data)

  • Manufacturer Applications: Not specified for this item; no application statements were provided.

Applicability for this compound type

  • SR101099 is offered as a Moligand™ screening-library small molecule. Primary applications are in discovery biology/chemistry workflows rather than as a general-purpose reagent or solvent.

Typical research uses (general)

  • Assay screening: Include in biochemical or cell-based panels to identify preliminary activity; capture results for SAR triage.
  • Orthogonal confirmation: Use multiple readouts (enzymatic activity, biophysical binding such as DSF, MST, SPR) to deconvolute false positives, aggregation, or redox interferences.
  • Chemoinformatics: Compute descriptors, flags (PAINS, Brenk), and similarity clusters to prioritize follow-up.
  • Hit follow-up: Generate analogs or purchase close neighbors for rapid SAR if activity is confirmed.

Practical notes

  • Ensure compound integrity: Confirm identity/purity pre-screen and post-hit via LC–MS; check for decomposition after long DMSO storage.
  • Control assays: Include detergent controls and redox scavengers (e.g., catalase, DTT absent) to rule out assay artifacts (general guidance; not item-specific).
Reaction Conditions

Not applicable

  • No reaction chemistry is specified for SR101099, and the structure is not provided. Therefore, typical reaction conditions, catalysts, or yields cannot be outlined for this item.

General assay-solution preparation (for screening use; not item-specific)

  • Prepare a primary DMSO stock (e.g., 10–50 mM subject to solubility). Vortex and, if needed, sonicate briefly. Filter through 0.22 μm PTFE for particulate removal.
  • For biochemical assays, dilute into buffer to the desired concentration, maintaining final DMSO at ≤0.5–1% v/v. Confirm absence of precipitation by visual inspection or nephelometry.
  • For cell-based assays, pre-warm media and add compound last to minimize precipitation; mix thoroughly and dose promptly.
Safety and Handling

Item-specific (from Product Data)

  • GHS Classification, Signal Word, H/P-Statements, Pictograms: Not specified for this item; refer to SDS.
  • Storage Conditions: Room temperature (per Product Data).

General laboratory safety (defer to SDS for authoritative guidance)

  • PPE: lab coat, safety glasses, and appropriate chemical-resistant gloves (e.g., nitrile). Use in a chemical fume hood to avoid inhalation of dust or vapors.
  • Avoid contact with skin, eyes, and clothing. Prevent aerosol generation during weighing and plate replication.
  • Incompatibilities: Unknown for this specific item. As a precaution, keep away from strong oxidizers, strong acids/bases, and ignition sources until the SDS is reviewed.
  • First aid overview: If on skin/eyes, rinse with water for at least 15 minutes; remove contaminated clothing. If inhaled, move to fresh air. If ingested, rinse mouth; do not induce vomiting unless directed by medical personnel. Seek medical attention for persistent symptoms.
  • Spill response: Avoid dust formation; collect with inert absorbent, transfer to chemical waste.
  • Waste disposal: Dispose according to institutional and local regulations; do not release to the environment.

Notes

  • Until a complete SDS is consulted, handle as a potentially harmful research chemical.
  • Screening-stock DMSO solutions should be clearly labeled and stored to minimize evaporation and cross-contamination.
Solvent Selection

Item-specific (from Product Data)

  • No solvent preferences are specified for SR101099; refer to CoA/Spec Sheet.

General guidance for small-molecule screening compounds

  • Primary stock solvent: DMSO is the default due to broad solvency, assay compatibility, and freeze–thaw resilience. Start at 10–50 mM depending on solubility.
  • Alternative organic solvents: DMF or NMP can dissolve challenging solids but have higher assay interference and safety burdens. Use sparingly and dilute into aqueous buffers with care.
  • Aqueous work: If ionizable, use appropriate buffers (e.g., phosphate, HEPES) at pH favoring solubilization; include 0.01–0.05% nonionic surfactant when needed to mitigate aggregation.
  • Volatile cosolvents: For chemistry workflows, EtOAc, MeCN, acetone, MeOH, or IPA may be used for purification or handling as applicable to the structure (unknown here; validate experimentally).

Selection tips

  • Build a mini solubility screen across: DMSO, MeOH, MeCN, PBS pH 7.4 (+/− 1% DMSO), and pH 2/9 buffers.
  • Monitor for precipitation upon dilution into assay buffers; keep final DMSO ≤0.5–1% v/v when possible.
  • Filter 0.22 μm prior to cell-based assays to remove particulates and aggregates.
Storage and Reconstitution

Item-specific (from Product Data)

  • Storage Conditions: Room temperature.
  • Shipped In: Not specified for this item; refer to CoA/Spec Sheet.
  • Appearance/Physical form: Not specified for this item; refer to CoA/Spec Sheet.

General guidance (not item-specific; confirm with CoA/SDS)

  • Solid storage: Keep tightly closed in a dry, inert atmosphere (desiccator recommended). Protect from prolonged light exposure until photostability is known.
  • DMSO stock solutions: Store aliquots at −20 to −80 C to minimize freeze–thaw cycles; many compounds are stable for months under these conditions. Allow to reach room temperature before opening to avoid moisture ingress.
  • Aqueous solutions: Prepare fresh when possible. If storage is necessary, keep at 2–8 C and assess stability (e.g., LC–MS) after 24–72 h.
  • Reconstitution: Begin with anhydrous DMSO; if higher aqueous content is required, titrate buffer slowly with mixing to avoid precipitation. Document final solvent composition for reproducibility.

Inventory control

  • Track lot/batch numbers in LIMS, record preparation dates and concentrations for all aliquots, and periodically verify concentration by UV or LC–MS where feasible.
Structure and Identity

Item-specific (from Product Data)

  • Product Name: SR101099 (SKU: S613689)
  • Catalog Category: Small molecules and compound libraries (小分子和化合物库)
  • Grade: Moligand™
  • CAS: S613689 (catalog placeholder; not a standard CAS format)
  • PubChem CID: 66720777
  • InChIKey: 414238 (truncated/atypical; verify on CoA/SDS)
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.

Interpretive notes (general)

  • Structural features, stereochemistry, and functional groups cannot be detailed without a definitive structure. Please consult the item’s Certificate of Analysis (CoA) or structure file (SDF/MOL) associated with CID 66720777 for exact atom connectivity and any chiral centers.
  • For screening-library compounds, 2D depictions typically show a single defined tautomer and protonation state suitable for storage and informatics; alternative protomers/tautomers may exist under assay conditions.

Data hygiene recommendations

  • Cross-check the InChIKey and SMILES against the provided SDF prior to registration or ELN use.
  • If you maintain a screening collection, capture: parent/base structure, major protonation state at pH 7.4, calculated logP/logD, and PAINS/REOS flags, to inform assay triage.
Synthetic Utility

Limited applicability

  • Without a disclosed structure, functional groups and reactivity patterns for SR101099 cannot be described. Consequently, its use as a synthetic building block or reagent cannot be recommended specifically.

General recommendations (if derivatization is contemplated)

  • Once the structure is confirmed, identify strategic handles (halogens, heteroatoms, carbonyls) for diversification via cross-coupling, amide formation, or SNAr as appropriate.
  • For library expansion, design analog sets varying lipophilicity (cLogP), H-bond donors/acceptors, and pKa to probe structure–property relationships while retaining the core scaffold.
Target Specificity

Item-specific (from Product Data)

  • No target, epitope, or binding specificity is provided for SR101099.

General note

  • As a Moligand™ screening molecule, any target engagement must be determined empirically. Use orthogonal assays (e.g., thermal shift, SPR/MST, enzymatic kinetics) and counterscreens to establish specificity and rule out assay interference.

Besoin d'aide pour choisir la qualité ?

Notre guide de sélection des qualités couvre la pureté, le statut du stabilisant et l'adéquation à l'application pour toutes les variantes de notre catalogue.

Voir le guide des qualités Moligand™ →

Souhaitez-vous que nous vous envoyions un message lorsque des réductions seront disponibles?

Me rappeler plus tard

Merci ! Veuillez vérifier votre boîte de réception e-mail pour confirmer.

Oups ! Les notifications sont désactivées.